Caspofungin versus liposomal amphotericin B for empirical therapy [1] (multiple letters)

New England Journal of Medicine

Volumn 352, Issue 4, 2005, Pages 410-414

  Kontoyiannis, Dimitrios P ^a   Lewis, Russell E ^a   Tattevin, Pierre ^b   Bareau, Benoît ^b   Camus, Christophe ^b   Marty, Francisco M ^c   Lowry, Colleen M ^c   Schneemann, Markus ^d   Imhof, Alexander ^d   Danaher, Patrick J ^e   Jones, Brian L ^f   McLintock, Lorna A ^g   Walsh, Thomas J ^h   Donowitz, Gerald R ⁱ   DePauw, Ben E ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e DAVID GRANT MEDICAL CENTER   (United States)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; GALACTOMANNAN; ITRACONAZOLE; PYRROLE; AMPHOTERICIN B; CYCLOPEPTIDE; AMPHOTERICIN B-DEOXYCHOLATE; DEOXYCHOLIC ACID; TRIAZOLE DERIVATIVE; LIPOSOME; PYRIMIDINE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; DRUG EFFICACY; FEVER; HUMAN; LETTER; LEUKEMIA; NEUTROPENIA; PRIORITY JOURNAL; MYCOSIS; NOTE; RISK ASSESSMENT; DRUG COMBINATION; ECONOMICS; INTRAVENOUS DRUG ADMINISTRATION; COMPARATIVE STUDY; SURVIVAL RATE; DRUG EFFECT; NEUTROPHIL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; FEVER; HUMANS; MYCOSES; NEUTROPENIA; PEPTIDES, CYCLIC; RISK ASSESSMENT; DEOXYCHOLIC ACID; DRUG COMBINATIONS; INFUSIONS, INTRAVENOUS; TRIAZOLES; LIPOSOMES; PYRIMIDINES; SURVIVAL RATE; ASPERGILLOSIS; NEUTROPHILS;

EID: 13744251323     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200501273520417     Document Type: Letter

References (0)